Innoforce Pharmaceuticals Co., Ltd, is located in Hangzhou Airport Economic Demonstration Area. The founders Dr. Guo-Liang Yu and Dr. Yuling Li are both former presidents of the Chinese biopharmaceutical Association-USA. Members of the core management team have stellar international track records with extensive expertise in technologies and business operations. The first phase of Innoforce campus covers an area of about 21 acres, with a total construction area of about 170,000 square meters. The campus includes biologic process development laboratories, scale-up lab and pilot facility and multiple sets of 2000L antibody production line with commercial GMP prodction capacities, plus Cell and Gene Therapy manufacturing suites. Innoforce’s goal is to establish top tier global development and biomanufacturing capabilities to facilitate development and commercialization of innovative medicines.
We specialise in intelligent & effective Search and believes in the power of partnerships to grow business.
Dr. Guo-Liang Yu is a well accomplished scientist and a successful serial entrepreneur. He currently is the global CEO of Apollomics Inc. (Formerly CBT Pharmaceuticals), an innovative therapeutics company devoted to curing cancer by combining immunology and other caner fighting methods. Before Apollomics Inc., Dr. Yu was the Executive Chairman of Crown Biosicence Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was acquired by JSR for $400 million in May of 2018. He co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and CEO for 10 years prior to its acquisition by Abcam for $170 million. He was also a venture partner at OrbiMed Venture LLC. Dr. Yu is the founding president of the Chinese Biopharmaceutical Association (CBA) and serves on the boards of several professional organizations in the United States and China, including BayHelix, Chinese-American Bio/Pharmaceutical Society (CABS), National Foundation of Cancer Research, Ray Wu Memori-al Foundation, and University of Pacific. He published over 40 papers and holds over 400 issued patents. Dr. Yu is generous in coaching young entrepreneurs, and he has co-founded a dozen startup companies in biotech and the healthcare sector, including Immune-Onc Therapeutics, Inc.in Palo Alto. Dr. Yu received his postdoc training from Harvard Medical School, Ph.D. degree under Dr. Elizabeth Blackburn (2009 Nobel Laureate) at Berkeley University, and his undergraduate training from Fudan University.×
Dr. Yuling Li is a seasoned executive with proven experience on biopharmaceutical development from clinical to commercialization. She serves as the Sr. Vice President of Process Development and Manufacturing of Apollomics Inc. Prior to joining Innoforce, she spent almost 10 years at MedImmune/Astra Zeneca where she was a Research and Development Director and Fellow in BioPharmaceutical Development. In that role, she provided strategic and scientific leadership across numerous biopharmaceutical process development and served as the CMC leader for multiple development program. Previously, she was the Senior Director of Purification Sciences at Human Genome Sciences, Inc. (now GlaxoSmithKline). Dr. Li played key roles in three approved products, contributed to more than thirty clinical development programs. She authored over forty publications and is the primary inventor for seven issued patents. Dr. Li has been a long-time member of industry expert groups to address issues and guidelines associated with biopharmaceutical development. She also established and led the industry postdoctoral program at MedImmune. In 2014, Dr. Li received the Rising Star Award from the Healthcare Business-women Association. Dr. Li served as the President (2007-2008) of the Chinese Biopharmaceutical Association-USA (CBA), and co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008. She is a member of the BayHelix group. Dr. Li received her Ph.D. from Robert Wood Johnson Medical School at Rutgers University.×
Dr. Carter is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development. Since 2010 he has been involved in starting several biotechnology companies as a co-founder, advisor, CEO, and/or member of the Board of Directors. Among other roles, Dr. Carter is currently Chairman of Neuralstem, Inc (NADAQ: CUR) in Germantown MD, USA a Senior Advisor to Innoforce, Inc. in Hangzhou, China. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharma-ceuticals. Under his leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology and completed an IPO and listing on the NASDAQ Stock Market. Earlier in his career, Dr. Carter was head of gene mapping at Human Genome Sciences, Inc. where he was involved in the discovery of dozens of novel human proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer. Dr. Carter is also engaged in a range of educational and teaching activities and holds an adjunct faculty position at Johns Hopkins University, where he teaches a course entitled “Creating a Biotechnology Enterprise”.×
Dr. Yingfei Wei has an extensive experience in biotechnology and pharmaceutical industry both as a scientist and as an executive. From 2006 to 2012, Dr. Wei served as the Chief Scientific Officer for 3SBio, Inc., a leading and the first NASDAQ listed Chinese bio-pharmaceutical company. From late 1998 to early 2004, Dr. Wei was with Bayer Biotech Research Division where she held a position as the Director of Cell and Analytical Biology. Prior to joining Bayer, Dr. Wei was one of the funding scientists in Human Genome Sciences Inc. in Maryland. She played key role in discovery of the HPNCC gene for colon cancer, which was nominated as “The Molecule of the Year” in by Science magazine in 1994.Dr. Wei received her bachelor’s degree from Peking University and PhD from UC Davis. She did her post-doc at Harvard School of Public Health. Dr. Wei is actively involved in biopharmaceutical-relat-ed associations including CABS, CBA, and BayHelix. She is also an advocator and participant in rural area early childhood education.×
Robert Valdes (Bob) has over 25 years of experience in the GMP Manufacturing sector and currently serves as co-founder of Biotech Resources Group (USA) and INNOASIA Ltd.(Hangzhou, PRC).
Prior to BRG, Bob was Director, Large-Scale Manufacturing at Human Genome Sciences (now GSK) where he oversaw the manufacture of HGS’ first commercial product. Bob was the first manufacturing engineer hired by HGS in 2000 for their Large-Scale Manufacturing facility design effort where he was very hands-on from Business Concept to Commercialization.
Prior to Bob’s 12-year tenure at HGS, he was employed by Lonza Biologics (US/UK) from 1994-2000 in various positions in gmp manufacturing design, start-up, and operations. His first job as an undergrad, Bob worked in Boston at Charm Sciences as a pilot-plant microbiologist where he cultivated, lyophilized, and tested a variety of microbes for use in approved food safety diagnostic devices. Mr. Valdes holds Master’s Degrees from the University of Massachusetts and Johns Hopkins and a B.A. in Microbiology from the University of New Hampshire.
View this video to understand our misson,capabilities and core strengths